Stromal cells within the tumor microenvironment play a supportive role in tumor growth, progression, and treatment resistance; therefore, these nonmalignant cells are potential therapeutic targets. In this issue of the JCI, Szot et al. devised a strategy to exploit the cellsurface marker TEM8 (also known as ANTXR1), which is expressed by cancer-associated stromal cells, as a zip code to deliver an antibody-drug conjugate (ADC) linked to the potent cancer-killing drug monomethyl auristatin E (MMAE). In preclinical tumor and experimental metastasis models of multiple cancer types, TEM8-ADC targeted TEM8-expressing cancerassociated stromal cells, which processed and liberated membrane-permeable MMAE and released this drug via the P-glycoprotein (P-gp) drug transporter. Released MMAE killed cancer cells through a bystander mechanism that did minimal damage to the stromal cells themselves. P-gp-expressing tumor cells displayed MMAE resistance, suggesting that P-gp expression status may identify patients who might benefit the most from TEM8-ADC. This strategy, termed DAaRTS (drug activation and release through stroma), represents an elegant example of how selective expression of a cell-surface molecule on cancerassociated stroma can be exploited to facilitate drug delivery and shrink solid tumors.
Targeting tumor stroma for anticancer therapy
The concept that solid tumors are heterogeneous communities of interdependent cell types, rather than homogeneous spheres of malignant cancer cells, has fundamentally changed the way we think about tumor progression and metastasis (1) . Moreover, viewing tumors in this way has revolutionized treatment strategies, because nonmalignant cells (i.e., stromal cells such as endothelial cells, pericytes, fibroblasts, and immune cells) within a tumor may be targeted to elicit anticancer activity. For example, antiangiogenic agents are prototypical stroma-targeted drugs and include both RTK inhibitors and antibodies that block VEGF signaling in the tumor endothelium (2) . While the effectiveness of anti-VEGF therapies has been limited by alternative angiogenesis pathways, tumor co-option of pre-existing vessels, and other complex mechanisms, this class of drugs has recently been repurposed and used at suboptimal doses to normalize the vasculature and boost the efficacy of immune checkpoint blockade (3) (4) (5) (6) . This exciting example illustrates how the cancer stroma can be exploited to achieve maximum benefit in combinatorial treatment regimens.
The effectiveness of stroma-targeted therapies depends, in part, on unique properties of the stromal cells themselves. Thus, distinct antigens expressed in the tumor stroma, especially surface antigens, are attractive targets for selective drug delivery to tumors. Almost 20 years ago, Brad St. Croix and coworkers provided a pioneering and highly influential publication that reported the first genome-wide analysis of mRNA expression in human tumor-associated endothelial cells (7) . From this study, several antigens were uncovered on the tumor vasculature and named tumor endothelial cell markers (TEMs, TEM1-9). Subsequent studies from the same group and others have confirmed the selective expression of various TEMs in the vasculature in mice and humans and across different tumor types (8) . However, some TEMs also frequently appear on vascular cells in healing wounds, in regenerative tissues such as the corpus luteum, and in unexpected cell types, including tumor cells, cancer-associated fibroblasts (CAFs), and other mesenchymal-lineage cells (9) . The promiscuous expression of TEMs in the vasculature in these different settings was not unexpected, because gene expression patterns in the endothelium are commonly shared during both pathological and physiological angiogenesis (10).
TEM8-targeting antibody drug conjugate
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shown to have potent metastasis-suppressing activity, as it prolonged survival in models of experimental metastasis to liver and lung. Although further evaluation in models of spontaneous tumor dissemination and genetically engineered mouse models will help confirm the activity of TEM8-ADC in primary tumors and their metastases, taken together, the results of the current study suggest that TEM8-ADC has durable antineoplastic effects at multiple stages of cancer progression. An important feature of TEM8-ADC is its tolerability in mice. Indeed, toxicological studies demonstrated mild but reversible toxicity in the gastrointestinal tract, an effect that appears dependent on murine carboxylesterase-1C, which cleaves MMAE from the ADC. Surprisingly, CAFs or tumor-associated endothelial cells were highly resistant to the TEM8-ADC, even though these cell types express tubule-disrupting synthetic analog of the natural product dolastatin) by a cathepsin B-cleavable dipeptide linker. In multiple tumor xenografts, including breast, colon, lung, ovarian, and pancreatic cancer cells, TEM8-ADC elicited potent and dose-dependent antitumor activity, whereas equivalent doses of unconjugated TEM8 antibody resulted in only modest reductions in tumor growth. Strikingly, 10% to 80% of mice were tumor free following TEM8-ADC treatment, depending on the type of cancer. Mice with established orthotopic breast tumors and pancreatic tumor xenografts showed a significant reduction of tumor burden when challenged with TEM8-ADC in combination with doxorubicin or gemcitabine compared with mice given monotherapy; thus, TEM8-ADC is not only effective as a single agent but also augments the efficacy of conventional cytotoxic agents. TEM8-ADC was also xenograft models (15) . Thus, while TEM8 appears to provide an advantage to cancer cells because of its auxiliary function(s), selective upregulation of this protein in the stroma also creates a vulnerability for cancer cells that can be exploited by antibody-drug conjugates (ADCs) and other targeted therapies.
ADCs combine the specificity of a mAb with a covalently linked cytotoxic molecule, thereby allowing for targeted delivery of a lethal payload to cancer cells. There are several critical considerations, including selection of the tumor antigen target, specificity of the antibody against the target, the toxic payload, and the linker connecting the antibody to the payload, that guide successful ADC development (16). Szot and colleagues generated a TEM8-targeting ADC consisting of a TEM8-specific mAb conjugated to monomethyl auristatin E (MMAE, a micro- Figure 1 . TEM8-ADC kills cancer cells via a bystander mechanism dependent on TEM8-expressing tumor stroma. The efficacy of the TEM8-ADC (i) as an antitumor agent is driven by DAaRTS. TEM8 expression in the tumor stroma, including fibroblasts, pericytes, and endothelial cells, localizes MMAE-linked TEM8-ADC to growing tumors (ii). Upon binding to stromal cells, the ADC is endocytosed and processed by lysosomal proteases such as cathepsin B (iii), thereby liberating cell-permeable MMAE that is exported by the drug transporter P-gp. Once MMAE is evicted from stromal cells, it is bioavailable to the rapidly proliferating cancer cells nearby (iv), where it induces apoptosis (provided these cancer cells do not express abundant P-gp themselves). For simplicity, processing of TEM8-ADC and eviction of free MMAE is only shown in CAFs; however, similar mechanisms may occur in cancer-associated pericytes and endothelial cells that also express TEM8.
ing CAFs surrounding pancreatic cancer cells as a means to deliver a lethal warhead. Together, these studies collectively demonstrate some of the creative ways that stroma-targeted therapies are currently being used to kill cancer cells.
An obvious limitation to the present work is the dependency on P-gp for the effectiveness of TEM8-ADC. According to the findings of Szot et al., only patients with low or absent P-gp expression on their cancer cells will respond to TEM8-ADC. Moreover, like other cytotoxicity-based therapies, it is possible that treatment with TEM8-ADC could promote the evolution of more aggressive cancers by inducing P-gp overexpression in tumor cells or selecting for subclones of cancer cells that express abundant P-gp. These P-gpexpressing tumor cells might evict MMAE just as the stromal cells do and potentially escape drug-induced apoptosis. To overcome this possibility, combinations of TEM8-ADCs that kill cancer cells via different mechanisms, or targeting TEM8 itself as an immunotherapeutic strategy using TEM8-directed chimeric antigen receptor T cells (CAR-T cells) could be used (18) . It is possible that the most effective strategy will require combinatorial approaches to attack cancer cells prior to the development of adaptive resistance.
Finally, some questions remain regarding the doses of the TEM8-ADC that are required to obtain maximal efficacy in this study. In particular, the doses used by Szot et al. are considerably higher than those used for most ADCs. Currently, there are over 60 ADC clinical trials, with more than 30 of these trials initiated after 2013, illustrating the excitement and promise surrounding the use of ADCs. Though there were minimal adverse effects in mice treated with high doses of TEM8-ADC, it is unclear whether similar results would be observed in humans. However, judicious combination of the TEM8-ADC with other agents could also help reduce the effective drug doses required in humans. Notably, the St. Croix group recently found that alternative warheads improve dosing and efficacy with a different stromatargeted ADC, suggesting that TEM8-ADCs may benefit from further optimization of drug-linker design (19) . In sum, the broad expression of TEM8 in the stroma of multiple cancer types and the apparent abundant TEM8 and internalize MMAE. Szot et al. have elegantly linked this finding to the mode of action of TEM8-ADC itself. Following TEM8-ADC endocytosis by TEM8-expressing stromal cells, MMAE is cleaved by intracellular proteases, such as cathepsin B, into a cell-permeable form that is subsequently exported by the transmembrane ATP-binding cassette drug transporter P-glycoprotein (P-gp). Because TEM8-positive stromal cells divide slowly and express high levels of P-gp compared with surrounding cancer cells, these cells are intrinsically drug resistant, whereas rapidly dividing cancer cells are drug sensitive (Figure 1 ). Once this bystander mechanism of action of TEM8-ADC was elucidated, Szot and colleagues were able to make predictions about which tumor cells would be TEM8-ADC responders on the basis of P-gp status. In accord with their hypothesis, cancer cells with abundant P-gp were more resistant to TEM8-ADC compared with their low P-gp counterparts. Moreover, TEM8-ADC-resistant cells could be sensitized in vitro with P-gp inhibitors. These results suggest that it is possible to predict responsiveness to TEM8-ADC therapy on the basis of P-gp levels in tumor cells.
Perspective
One of the most impressive and exciting findings in the present study by Szot et al. is the generalizability of TEM8-ADC that is perhaps related to the prevalent TEM8 expression in the tumor stroma at multiple anatomical sites. Using immunohistochemistry, the authors found that TEM8 was expressed in the stroma of approximately 70% of the tumors studied but was undetectable in almost all corresponding adjacent normal tissues. In 11 tumor models, TEM8-ADC either caused regression or complete inhibition of tumor growth. Even in notoriously hard-to-treat pancreatic cancer, TEM8-ADC diminished tumor growth and extended the length of survival by approximately 175%. Pancreatic cancers are well known to have a dense stromal infiltrate that is thought to act as a barrier against drug delivery, and eliminating this stromal barrier through various pharmacological approaches to improve drug delivery has been attempted (17) . Using an opposite approach, Szot and colleagues instead exploit TEM8-express-
